Related Experiment Video
Updated: Mar 29, 2026
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
Melanoma: oncogenic drivers and the immune system
Niki Karachaliou1, Sara Pilotto1, Cristina Teixidó1
11 Instituto Oncológico Dr Rosell, Quiron-Dexeus University Hospital, Barcelona, Spain ; 2 Department of Medical Oncology, University of Verona, Azienda Ospedaliera Universitaria Integrata, Verona, Italy ; 3 Pangaea Biotech, Quirón Dexeus University Institute, Barcelona, Spain ; 4 Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain ; 5 Medical Oncology Unit, Human Pathology Department, University of Messina, Messina 98122, Italy ; 6 Instituto Oncológico de Córdoba, Córdoba, Argentina ; 7 Molecular Oncology Research (MORe) Foundation, Barcelona, Spain ; 8 Germans Trias i Pujol Health Sciences Institute and Hospital, Campus Can Ruti, Barcelona, Spain.
Recent advances in understanding melanoma biology have revolutionized treatment. Targeted therapies for BRAF mutations and immunotherapies targeting immune checkpoints offer new hope for patients with advanced melanoma.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Melanoma was historically considered highly therapy-resistant.
- Significant progress in understanding melanoma biology over 30 years.
- Identification of key molecular drivers and immune evasion mechanisms.
Purpose of the Study:
- To review the molecular biology of melanoma.
- To highlight recent advances in targeted and immunotherapeutic approaches.
- To discuss the evolving treatment landscape for melanoma.
Main Methods:
- Review of current scientific literature.
- Analysis of molecular pathways in melanoma.
- Examination of clinical trial data for targeted therapies and immunotherapies.
Main Results:
- BRAF mutations are key drivers in up to 50% of melanomas, enabling targeted therapy.
- Inactivation of immune checkpoints offers new avenues for cancer immunotherapy.
- Molecularly targeted and immunotherapeutic strategies have transformed treatment for unresectable and metastatic melanoma.
Conclusions:
- Melanoma treatment has shifted from a therapy-resistant model to one with effective molecularly targeted options.
- Targeting BRAF mutations and immune checkpoints represents major therapeutic breakthroughs.
- Continued research into melanoma's molecular and immune landscape promises further treatment advancements.
Related Concept Videos
01:27Tumor Immunotherapy
01:30Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
02:17The Tumor Microenvironment
02:17The Tumor Microenvironment
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
02:53Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...